ADVERTISEMENTs
_page-0001.jpg)
Two Indian American–led firms on TIME100 Most Influential Companies 2025 list
The companies were recognized for its advancements in gene therapy and drug development.
-
Bhavana P - Tue, 22, Jul 2025
- 15:03 EDT
- 37
(L-R) Reshma Kewalramani (Image- Vertex Pharmaceuticals) and Samarth Kulkarni (Image- CRISPR Therapeutics) /
TIME has unveiled its 2025 list of the 100 Most Influential Companies, featuring two biotech powerhouses led by Indian-American CEOs: Vertex Pharmaceuticals and CRISPR Therapeutics.
Vertex Pharmaceuticals, led by Reshma Kewalramani was recognized under the “Impact Awards” category, which recognizes top five standout companies making meaningful contributions in their fields. CRISPR Therapeutics, led by Samarth Kulkarni, was recognized under the “Pioneers” category.
Also read:Four Indian Americans named on TIME100 Creators List
Vertex Pharmaceuticals earned praise for its game-changing pipeline, including Casgevy, the first FDA-approved CRISPR-based treatment for sickle cell disease and beta thalassemia. Vertex also launched Journavx, the first non-opioid painkiller approved in over two decades. Kewalramani’s strategy of targeting diseases with high unmet need through rational drug design has fueled Vertex’s rise to a $114 billion market cap.
“Why did we do this? Because we thought pain was an incredibly important disease where there was no innovation and where we thought we could make a big difference. And why did we keep going? Because of the science and our desire to work in areas where we could make this kind of transformative leap,” said Kewalramani.
Vertex is also advancing a cell-based cure for type 1 diabetes and accelerating chronic kidney disease treatments with its $4.9 billion acquisition of Alpine Immune Sciences.
Meanwhile, CRISPR Therapeutics continues to push the boundaries of gene editing. Known for co-developing Casgevy, the company is now testing Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) applications for high cholesterol and lupus—common diseases with significant global burden.
“Since our founding, CRISPR Therapeutics has been driven by a mission to transform medicine through bold science and meaningful innovation. We are honored to be recognized by TIME. This acknowledgement is testament to the extraordinary dedication and collaboration across our teams to pioneer the next frontier of genetic medicine and improve the lives of patients around the world,” said Kulkarni.
Related
 (1).jpg)
.jpg)
.jpg)
.JPG)
.jpg)
.jpg)
.jpg)
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login